-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Neutral on Abivax, Lowers Price Target to $118

Benzinga·09/22/2026 12:40:54
Listen to the news
Wedbush analyst David Nierengarten maintains Abivax (NASDAQ:ABVX) with a Neutral and lowers the price target from $140 to $118.